Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rasagiline. Teva Pharmaceutical.

Andreas Kupsch1

  • 1Department of Neurology, Charite-Virchow, Berlin, Germany. andreas.kupsch@charite.de

Current Opinion in Investigational Drugs (London, England : 2000)
|July 2, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinicians' viewpoints on current paradigms of care and research in Parkinson's disease.

Journal of neural transmission (Vienna, Austria : 1996)·2024
Same author

Absorption Correction for 3D Elemental Distributions of Dental Composite Materials Using Laboratory Confocal Micro-X-ray Fluorescence Spectroscopy.

Analytical chemistry·2024
Same author

Simulation-Assisted Augmentation of Missing Wedge and Region-of-Interest Computed Tomography Data.

Journal of imaging·2024
Same author

Micro-CT analysis and mechanical properties of low dimensional CFR-PEEK specimens additively manufactured by material extrusion.

Journal of the mechanical behavior of biomedical materials·2023
Same author

Diffraction Enhanced Imaging Analysis with Pseudo-Voigt Fit Function.

Journal of imaging·2022
Same author

Renaming of Hallervorden-Spatz disease: the second man behind the name of the disease.

Journal of neural transmission (Vienna, Austria : 1996)·2021
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Rasagiline, an irreversible MAO(B) inhibitor, is in late-stage trials for neurological disorders like Parkinson's disease. Anticipated market launch is expected soon, with significant sales projections.

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Rasagiline is a selective, irreversible monoamine oxidase type B (MAO-B) inhibitor.
  • It is under development for treating neurological diseases, particularly Parkinson's disease (PD).

Purpose of the Study:

  • To summarize the development status and market projections for rasagiline.
  • To highlight its potential in treating Parkinson's disease and Alzheimer's disease (AD).

Main Methods:

  • Review of clinical trial phases (Phase II and III) and regulatory filings.
  • Analysis of market predictions and sales forecasts from financial analysts.

Main Results:

  • Rasagiline has advanced to Phase III trials for Parkinson's disease in key global markets.

Related Experiment Videos

  • Projected market launch dates and significant sales figures have been forecasted by industry analysts.

    • Conclusions:

    • Rasagiline shows promise as a therapeutic agent for neurological conditions.
    • The drug is nearing market entry, with substantial commercial potential anticipated.